Cellectar Biosciences, Inc.
corporate_fare Company Profile
Cellectar Biosciences, Inc. (NASDAQ:CLRB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for CLRB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for CLRB spans 10-Q, 8-K, 424B3, DEF 14A.
Recent high-impact activity:
- Cellectar Posts 46c Per-Share Q3 Loss as Cash Runway Tightens
- Cellectar Q3 Loss Widens to $8.0M; Going Concern Reaffirmed With Runway to Q2 2027
- Cellectar's Iopofosine Shows 79.2% Major Response in BTKi-Refractory WM, Phase 3 and NDA Planned
- Cellectar Advances Iopofosine Toward Mid-2027 NDA, Reports Q2 Loss and $34M Cash
- Cellectar Advances Iopofosine Toward Mid-2027 NDA, Reports Q2 Loss of $6.9M
Financial Snapshot
Short Interest & Short Volume
1.65 days to coverFINRA reported short interest of 218,774 shares in CLRB as of the October 30, 2026 settlement, a 17.0% decrease from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 47.3% of CLRB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CLRB, detected from its recent SEC filings · based on capital-structure filings through 2026-06-02.
Resale Registration Finalized · Origin of Shares
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →